Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business.

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

CSL has reported a 7% net profit rise for the December half, with its blood-derived products offsetting weak flu vaccination ...

This would aid the volume of plasma collected per center, but also reduce blood donor screening. We also think CSL benefits from superior fractionation expertise and quality processes, enabling ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

The ASX-listed giant says it can switch manufacturing sites if Donald Trump imposes tariffs on pharmaceuticals. It expects ...

Australian biopharmaceutical company CSL reported a drop in vaccine sales due to falling immunization rates in the U.S., its largest market. The decline contributed to lower-than-expected profits, ...

Pharmaceuticals company CSL on Tuesday reported a 3% rise in first-half profit, benefiting from further growth in its main blood-plasma business. Australia-based CSL, which runs a network of ...